Peptide-modified mesoporous silica nanoparticles for the coordinated regulation of macrophage polarization and pyroptosis in the treatment of implant-related infections

Implant-related infections (IRIs) present a significant challenge in clinical treatment because of the formation of biofilms. The complex architecture of biofilms not only impedes antibiotic penetration, fostering the evolution of multidrug resistance in bacteria under minimal selective pressure but also suppresses the antimicrobial activity of macrophages and induces their pyroptosis in large quantities. This excessive pyroptosis impairs the collective immune function of macrophages, enabling pathogens to evade immune system clearance and rendering infection difficult to eradicate. Existing treatment strategies often necessitate extensive surgical debridement, which not only causes significant harm to patients' physiological health and quality of life but also results in limited therapeutic outcomes. To address these challenges, this study developed a mesoporous silica nanoparticle system (MRL) modified with the RGD (Arginine-Glycine-Aspartic acid) tripeptide and loaded with the antimicrobial peptide LL-37. The LL-37 released from MRL can not only directly disrupt bacterial cell membranes, preventing bacteria from developing resistance through conventional mutation mechanisms, but also enhance antimicrobial activity by modulating macrophage polarization toward the M1 phenotype. However, LL-37 may induce and exacerbate macrophage pyroptosis within biofilms. Therefore, we modified the nanoparticles with RGD to increase macrophage viability and reduce their number of deaths, thereby alleviating the immunosuppression caused by excessive macrophage pyroptosis. In vitro and in vivo experiments demonstrated that MRL, while preserving the antimicrobial activity and immunomodulatory function of LL-37, significantly reduced macrophage pyroptosis and protected the collective immune activity of macrophages. Thus, the fine-tuned regulation of immune response was achieved, providing new insights and strategies for the treatment of IRIs.

Authors

Institutions

Publication Details

Journal
Materials Today Bio
Published
2025-03-04
DOI
https://doi.org/10.1016/j.mtbio.2025.101629
Citations
6
Primary Topic
Inflammasome and immune disorders
Type
article
Field-Weighted Citation Impact
4.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Peptide-modified mesoporous silica nanoparticles for the coordinated regulation of macrophage polarization and pyroptosis in the treatment of implant-related infections

Jiaxiang Bai, Ming‐you Xu, Chang Liu, Xingshi Yuan et al.
6 citations
Materials Today Bio
Inflammasome and immune disorders
4.84
article

Peptide-modified mesoporous silica nanoparticles for the coordinated regulation of macrophage polarization and pyroptosis in the treatment of implant-related infections

Jiaxiang Bai, Ming‐you Xu, Chang Liu, Xingshi Yuan, Zhi Li, Xiaofang Wang, Yuhang Wang, Zhu Chen, Pei Wei, Xifu Shang
article en
6 citations

Abstract

Implant-related infections (IRIs) present a significant challenge in clinical treatment because of the formation of biofilms. The complex architecture of biofilms not only impedes antibiotic penetration, fostering the evolution of multidrug resistance in bacteria under minimal selective pressure but also suppresses the antimicrobial activity of macrophages and induces their pyroptosis in large quantities. This excessive pyroptosis impairs the collective immune function of macrophages, enabling pathogens to evade immune system clearance and rendering infection difficult to eradicate. Existing treatment strategies often necessitate extensive surgical debridement, which not only causes significant harm to patients' physiological health and quality of life but also results in limited therapeutic outcomes. To address these challenges, this study developed a mesoporous silica nanoparticle system (MRL) modified with the RGD (Arginine-Glycine-Aspartic acid) tripeptide and loaded with the antimicrobial peptide LL-37. The LL-37 released from MRL can not only directly disrupt bacterial cell membranes, preventing bacteria from developing resistance through conventional mutation mechanisms, but also enhance antimicrobial activity by modulating macrophage polarization toward the M1 phenotype. However, LL-37 may induce and exacerbate macrophage pyroptosis within biofilms. Therefore, we modified the nanoparticles with RGD to increase macrophage viability and reduce their number of deaths, thereby alleviating the immunosuppression caused by excessive macrophage pyroptosis. In vitro and in vivo experiments demonstrated that MRL, while preserving the antimicrobial activity and immunomodulatory function of LL-37, significantly reduced macrophage pyroptosis and protected the collective immune activity of macrophages. Thus, the fine-tuned regulation of immune response was achieved, providing new insights and strategies for the treatment of IRIs.

Materials Today BioVol. 31
Tongji University (CN), University of Science and Technology of China (CN), Anhui Medical University (CN), Shanghai Tenth People's Hospital (CN), Second Affiliated Hospital of Anhui Medical University (CN)
Openalex Percentile: Top 5%
Inflammasome and immune disorders
4.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.